DrugPatentWatch Database Preview

Patent: 10,035,817

« Back to Dashboard

Summary for Patent: 10,035,817

Title:	Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
Abstract:	The invention provides processes for preparing purified cell-binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell-binding agent cytotoxic agent conjugate and one or more impurities to a polyvinyl difluoride (PVDF) membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell-binding agent cytotoxic agent conjugate.
Inventor(s):	Chen; Xiaoxi Kevin (Natick, MA), Li; Xinfang (Newton, MA)
Assignee:	IMMUNOGEN, INC. (Waltham, MA)
Application Number:	14/430,701
Patent Claims:	see list of patent claims

Details for Patent 10,035,817

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		IMMUNOGEN, INC. (Waltham, MA)	2032-10-04	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	002	1997-11-26		IMMUNOGEN, INC. (Waltham, MA)	2032-10-04	RX		search
Genentech	HERCEPTIN	trastuzumab	VIAL; INTRAVENOUS	103792	001	1998-09-25		IMMUNOGEN, INC. (Waltham, MA)	2032-10-04	RX	Orphan	search
Genentech Inc	RITUXAN HYCELA	rituximab; hyaluronidase (human recombinant)	SOLUTION;SUBCUTANEOUS	761064	001	2017-06-22		IMMUNOGEN, INC. (Waltham, MA)	2032-10-04	RX	Orphan	search

International Patent Family for US Patent 10,035,817

Country	Patent Number	Estimated Expiration
Australia	2013326881
Australia	2018241056
Canada	2886993
China	105209592